Online inquiry

IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1828MR)

This product GTTS-WQ1828MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CFD gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317335.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1675
UniProt ID P00746
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1828MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11926MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ9144MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ12356MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ708MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ5055MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ6959MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ9701MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW